Saturday, August 2, 2025

Latest

Moderna Expands Manufacturing Abilities In Spain, Steps Into New Asian Markets

Moderna Inc (NASDAQ: MRNA) is looking to scale up the production of its mRNA vaccines and therapeutics on a global level. The firm this morning announced a significant expansion within Asian markets, following the news last night that the company is expanding its operations in Spain.

In terms of its operations in Spain, the firm last night indicated it has expanded a long-term collaboration agreement that was previously in place. The collaboration, which is with its partner Laboratorios Farmacéuticos Rovi, S.A, will see the expansion of current capacity for the manufacturing of Moderna’s products within the country.

Presently, Rovi operates several facilities near Madrid where Moderna’s vaccines are produced. The new arrangement expands the working agreement between the two firms for a period of ten years. Presently, the arrangement will see the scaling of the manufacturing of COVID-19 vaccines, while in the future the agreement will facilitate the production of future mRNA vaccine candidates. Included in the arrangement is a series of investments that are said to support the purchase of additional equipment for production lines.

Products produced at the facility are currently used within countries outside of the United States.

In terms of Asian markets, the company this morning announced that it will be establishing new subsidiaries within Hong Kong, Taiwan, Singapore and Malaysia which will be used to “support the delivery of mRNA vaccines and therapeutics.” The expansion of the commercial network follows the company scaling the production of its current vaccine, as well as future mRNA vaccines and therapeutics. The drive to expand within Asian markets is a result of the region reportedly bearing “the highest burden of infectious diseases.”

Moderna’s portfolio currently consists of 40 development programs. 25 of these programs are currently in varying stages of clinical trials.

Moderna last traded at $151.12 on the Nasdaq.


Information for this briefing was found via Edgar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why Gold’s Bull Run May Just Be Getting Started! | Peter Grandich

Tariffs Spark New Race for Critical Metals | Rob McEwen

Antimony Resources: The Bald Hill Project

Recommended

Tsunami Warnings Spread As Largest Quake Since 2011 Hits Russia

Northern Superior Intersects 1.75 g/t Gold Over 65.0 Metres At Philibert

Related News

No, The CEO Of Moderna Didn’t Just Dump $400 Million In Shares

The trouble with social media, is that it’s a big game of telephone. One individual...

Sunday, February 13, 2022, 02:50:29 PM

Moderna and Merck & Co: mRNA Cancer Vaccine Shows “Highly Encouraging Results,” Shares Rise

On Tuesday, Moderna (NASDAQ: MRNA) announced that their personalized cancer-vaccine program was successful in a...

Wednesday, December 14, 2022, 01:06:00 PM

Moderna Shares Jump After Announcing Q4 2021 Earnings, US$19 Billion Advanced Sales

Moderna Inc (Nasdaq: MRNA) announced this morning its Q4 and full-year 2021 earnings. The vaccine manufacturer...

Thursday, February 24, 2022, 10:51:00 AM

Internal Moderna Report Tags Elon Musk, Novak Djokovic, and Russell Brand as ‘High Risk’

Moderna (NASDAQ: MRNA), the Boston-based pharmaceutical company known for its mRNA Covid-19 vaccine, has reportedly...

Tuesday, November 28, 2023, 01:06:00 PM

Moderna Shares Soar As Company Announces $3 Billion Stock Buyback

Moderna Inc (NASDAQ: MRNA) shares on Wednesday soared as high as 17% after it announced...

Thursday, August 4, 2022, 08:26:43 AM